Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Case Report

Volume 9, Number 1-2, April 2020, pages 13-17

Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia

Figure

Figure 1.
Figure 1. Pretreatment images showing blasts in the bone marrow and peripheral blood (a, b) and bone marrow hypercellularity (c). Bone marrow aspirate after two cycles of chemotherapy showing marked hypocellularity consistent with chemoablation (d). Post-recovery bone marrow aspirate and core biopsy showing recovered bone marrow (e, f).

Tables

Table 1. Favorable and Unfavorable Risk Factors for Outcomes in Adults With Acute Myeloid Leukemia [6]
 
Favorable factorsUnfavorable factors
Age < 50 yearsAge > 60 years
Karnofsky score > 60%Karnofsky score < 60%
MDR 1-negative phenotypeMDR 1-positive phenotype
No antecedent hematologic disorder or prior chemotherapy or radiotherapyTherapy-related AML, prior myelodysplastic syndrome, myeloproliferative or other hematologic disorder
t(8;21), inv(16)/t(16;16), t(15;17)Complex karyotypic abnormalities, -5, -7, 3q26 aberrations, t(6;9), 11q23 aberrations except for t(9;11), “monosomal karyotype”

 

Table 2. The 2017 ELN Risk Stratification by Geneticsa
 
Risk categoryFavorableIntermediateAdverse
aAdapted from Estey [3].
Genetic abnormalityt(8;21)(q22;q22.1); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 mutated NPM1 without FLT3-ITD or with FLT3-ITDlow = allelic ratio > 0.5; biallelic mutated CEBPAMutated NPM1 and FLT3-ITDhigh = allelic ratio > 0.5; wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without adverse-risk genetic lesions); t(9;11)(p21.3;q23.3); MLLT3-KMT2A; cytogenetic abnormalities not classified as favorable or adverset(6;9)(p23;q34.1); DEK-NUP214 t(v;11q23.3); KMT2A rearranged t(9;22)(q34.1;q11.2); BCR-ABL1 inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 25 or del(5q); -7; -17/abn(17p); complex karyotype monosomal karyotype; wild-type NPM1 and FLT3-ITDhigh; mutated RUNX; mutated ASXL1; mutated TP53